Trial Profile
To evaluate efficacy and safety of Apatinib treatment in patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer